Skip to Content
MayoACCESS
MayoLINK
Register
My Dashboard
Test Catalog
Algorithms
Download Test Catalog & Interpretive Handbook
New Tests
NY State Informed Consent Tests
Performing Locations
Referred Tests
Specialty Testing
Test Updates
Ordering & Results
Critical Values & Results
Custom Gene Ordering
Forms
LIS Resources
MayoACCESS Resources
MayoLINK Resources
Order Your First Test
Patient Information and Signature Forms
Request Additional Testing
Send Additional Specimen
Specimen Handling
Collection & Preparation
Dangerous Goods Training
Shipping & Courier Guides
Shipping Regulations
Supplies
Customer Service
Billing
Contact Us
FAQ
IT Updates
Operational Updates
Quality & Compliance
Education & Insights
Educational Resources
News
Outreach
Podcasts
Stories
Contact
Log Out
Return to Answers From the Lab
Assay identifies patients eligible for new ovarian cancer drug: Maryam Shahi, M.D.
By
Samantha Rossi
• April 23, 2024
Share this:
Related Episodes
How the Evolving Role of Diagnostics and Platforms Impact Healthcare: Bill Morice, M.D., Ph.D.
By
Sarah Jarvis
•
July 3, 2025
Labile Copper Test Enhances Evaluation for Wilson’s Disease: Joshua Bornhorst, Ph.D.
By
Samantha Rossi
•
July 1, 2025
Assay Aids Diagnosis of Resistant Hypertension: John Lieske, M.D., and Sandra Taler, M.D.
By
Samantha Rossi
•
June 24, 2025
Samantha Rossi
Samantha Rossi is a Digital Marketing Manager at Mayo Clinic Laboratories. She supports marketing strategies for product management and specialty testing. Samantha has worked at Mayo Clinic since 2019.
Related Posts
How the Evolving Role of Diagnostics and Platforms Impact Healthcare: Bill Morice, M.D., Ph.D.
Labile Copper Test Enhances Evaluation for Wilson’s Disease: Joshua Bornhorst, Ph.D.
Neurodegenerative Diseases: Diagnostic Advancements
